NCT05336721 - A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2021

Primary Completion Date

October 31, 2024

Study Completion Date

November 5, 2024

Conditions

Triple-negative Breast Cancer

Interventions

DRUG

Chiauranib

25mg/35mg/50mg orally once daily

DRUG

capecitabine

1000mg/m2 on Days 1-14 in a repeating 21-day cycle

Trial Locations (4)

Jiangsu Province Hospital, Nanjing

Henan Cancer Hospital, Zhengzhou

Sun Yat-sen University Cancer Center, Guangzhou

The Fifth Medical Center of PLA General Hospital, Beijing